

Press release

Stockholm 17 October 2024

Invitation to presentation of Bactiguard's interim report for the third quarter 2024

Bactiguard Holding AB (publ) publishes its interim report for the third quarter on Thursday 24 October 2024 at 07:00 CET.

In connection with this, Bactiguard will host an audiocast for investors, analysts, and media at 11:00 CET. CEO Christine Lind will present the report and answer questions together with CFO Patrick Bach. The report and a presentation will be available at ir.bactiguard.com.

To participate in the audiocast, please use this link: ir.bactiguard.com/report/q3-2024/

To participate only by conference call, please register via the link above. Questions can be asked either in writing via the audiocast or orally if you attend the conference call.

For further information, please contact:

Patrick Bach, CFO +46 761 295 911

Nina Nornholm, Head of Communications & Investor Relations +46 708 550 356

About Bactiguard

Bactiguard is a global MedTech company developing safe and biocompatible technology to prevent medical device related infections. The company's unique technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard's infection prevention solutions decrease patient suffering, save lives, and unburden healthcare resources while also fighting against antimicrobial resistance, one of the most serious threats to global health and modern medicine. Bactiguard operates through license partnerships with leading global MedTech companies that apply the technology to their medical devices and sell them under their own brand or co-branded with Bactiguard. The company also has a portfolio of wound management products.

Bactiguard is headquartered in Stockholm and listed on Nasdaq Stockholm.

Read more about Bactiguard: www.bactiguard.com

Follow Bactiguard on [LinkedIn](#)